FeesSafety
Pluang+

Viatris completes acquisition of Pacira, boosting its non-opioid pain management portfolio.

Company Fundamentals
17 Nov 2026, 15:50 WIB
PRNewsWire
View Source
Bullish
Viatris completes acquisition of Pacira, boosting its non-opioid pain management portfolio.

Viatris has finalized its acquisition of Pacira BioSciences, a leader in non-opioid pain management, for $36.50 per share. This move strengthens Viatris' U.S. innovative medicines business by combining complementary portfolios and expertise. The acquisition is expected to add $90-$100 million in revenue for the remainder of 2026. Pacira will be delisted from Nasdaq and become a wholly owned subsidiary of Viatris, positioning the company as a leader in non-opioid pain treatments.

Viatris shares trade at USD 20.58 on Pluang as of Nov 17, 2026 21:01 WIB, down 0.77% for the day. The company holds a market cap of $23.78 billion and a dividend yield of 2.31%. This trading activity comes shortly after Viatris completed its acquisition of Pacira BioSciences, enhancing its position in non-opioid pain management.

More News (VTRS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App